布地奈德-福莫特罗与特布他林缓解剂在维持吸入糖皮质激素的成人哮喘患者中的比较(INFORM ASTHMA):一项开放标签、平行组、随机对照4期试验
该开放标签随机对照4期试验在新西兰纳入181例使用维持吸入糖皮质激素的轻度至中度哮喘成人,比较布地奈德-福莫特罗与特布他林作为缓解剂。两组不良事件发生率相似,无死亡。结论认为布地奈德-福莫特罗缓解剂是短效β2受体激动剂的安全有效替代。
要点
- 布地奈德-福莫特罗缓解剂较特布他林显著降低第26周FeNO。
- 两组不良事件发生率无显著差异,安全性相似。
- 研究支持在维持ICS的成人哮喘中用布地奈德-福莫特罗替代SABA缓解剂。
核心结论
- 在维持吸入糖皮质激素的成人哮喘患者中,布地奈德-福莫特罗缓解剂较特布他林缓解剂降低第26周FeNO,且安全性相似。
研究设计与样本
- 开放标签、平行组、随机对照4期试验,在新西兰惠灵顿医院和两个社区初级保健机构进行。
- 纳入181例16-75岁、医生诊断哮喘、使用维持ICS、入组前12周平均每周使用缓解剂≥2次且筛选时FeNO≥25 ppb的成人,随机1:1分为布地奈德-福莫特罗组(n=93)和特布他林组(n=88)。
- 所有参与者接受维持布地奈德200 μg,治疗期26周,主要终点为意向性治疗人群第26周FeNO。
临床怎么用
- 对于使用维持吸入糖皮质激素的成人哮喘患者,可考虑使用布地奈德-福莫特罗作为缓解剂替代短效β2受体激动剂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recommendations for the use of inhaled corticosteroid-formoterol reliever-based regimens are limited by the absence of randomised controlled trials (RCTs) in patients with asthma using maintenance inhaled corticosteroids, and scarce evidence for the effect on type 2 airway inflammation. We aimed to examine the clinical efficacy and safety of maintenance inhaled corticosteroids plus budesonide-formoterol reliever or terbutaline reliever in patients with mild-to-moderate asthma. METHODS: This open-label, parallel-group, randomised, controlled, phase 4 trial was conducted at Wellington Hospital and two community-based primary care facilities in New Zealand. Eligible participants were aged 16-75 years, had a self-reported doctor's diagnosis of asthma, were using reliever only therapy or maintenance inhaled corticosteroids with short-acting β2-agonist reliever therapy, and were registered with a general practitioner. Participants had to have reported mean reliever use on two or more occasions per week in the 12 weeks before enrolment and had evidence of airway inflammation (FeNO ≥25 parts per billion [ppb]) at screening. Participants were randomly assigned (1:1) to budesonide-formoterol (budesonide 200 μg and formoterol 6 μg) reliever or terbutaline 250 μg reliever therapy using a computer-generated sequence in block sizes of four and six, stratified by region, baseline inhaled corticosteroids maintenance dose, and history of severe asthma exacerbation in the previous 12 months. All participants received maintenance budesonide 200 μg. During a 26-week treatment period, participants attended visits at weeks 0 (screening and randomisation), 13, and 26. The primary outcome was FeNO at week 26, measured in the intention-to-treat (ITT) population. This trial is registered with the Australian New Zealand Clinical Trials Registry, ACTRN12622001304729 (completed). FINDINGS: Between March 28, 2023, and Aug 27, 2024, 290 participants were assessed for eligibility, 109 were ineligible, and 181 were randomly assigned to budesonide-formoterol (n=93) or terbutaline reliever therapy (n=88; ITT population). Participants had a mean age of 33·91 years (SD 15·54). 119 (66%) of 181 participants were female and 62 (34%) were male. Geometric mean FeNO was 62·18 ppb (SD 1·86) at baseline and 39·65 ppb (2·12) at week 26, for the budesonide-formoterol group and 68·03 ppb (1·97) at baseline and 52·98 ppb (2·27) at week 26 for the terbutaline group. Budesonide-formoterol reliever therapy resulted in a mean reduction in geometric mean FeNO of 18·50% (95% CI 2·72-31·73; p=0·024) at week 26 compared with terbutaline reliever therapy. 77 (83%) of 93 participants in the budesonide-formoterol group versus 69 (78%) of 88 in the terbutaline group had at least one adverse event (relative risk 1·06 [95% CI 0·91-1·22]; p=0·46). There were no deaths in the study. INTERPRETATION: Budesonide-formoterol reliever therapy resulted in a reduction in FeNO compared with terbutaline reliever in adults with asthma using maintenance inhaled corticosteroids. Budesonide-formoterol reliever is a safe and effective alternative to short-acting β2-agonist reliever therapy for adults using maintenance inhaled corticosteroids. FUNDING: AstraZeneca.
引用
- Noble, Bean, Perry, et al. Budesonide-formoterol versus terbutaline reliever in adults with asthma using maintenance inhaled corticosteroids in New Zealand (INFORM ASTHMA): an open-label, parallel-group, randomised, controlled, phase 4 trial. Lancet Respir Med. 2026. PMID: 41520676. doi:10.1016/S2213-2600(25)00327-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。